Drug intelligence / Profile preview

IN-G00002

Development stage: Unknown
Lead developer: HK inno.N Corporation
Modality: Small Molecules

Overview

IN-G00002 is an investigational drug developed by HK inno.N. As of the latest available information, its mechanism of action has not been disclosed. The drug is currently being evaluated in a Phase 1 clinical trial for atrial fibrillation in Korea. No additional details regarding its modality, route of administration, or specific pharmacological class have been made public[1][2]. A bioequivalence study comparing IN-G00002 to another compound (IN-R00002) has also been conducted in healthy adult volunteers[2].

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on IN-G00002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN-G00002.

Explore the full profile